Ellevest Inc’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Ellevest Inc’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-365	Closed	-$3.93K	–	1021
2023 Q1	$3.93K	Hold	365	–	–	﹤0.01%	1274
2022 Q4	$5.47K	Hold	365	–	–	﹤0.01%	1166
2022 Q3	$5K	Buy	+365	New	+$4.16K	﹤0.01%	1181
2020 Q3	–	Sell	-6	Closed	–	–	1226
2020 Q2	$0	Sell	6 -17	-74%	-$355	﹤0.01%	1230
2020 Q1	$0	Buy	23 +5	+28%	+$78	﹤0.01%	1200
2019 Q4	$0	Buy	+18	New	+$156	﹤0.01%	1014

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Ellevest Inc's KNSA Position: Q2 2023 in Review

Ellevest Inc sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2023, closing a stake of 365 shares — an estimated $3.93K sold.

Ellevest Inc first reported a position in KNSA in Q4 2019 and held it in 6 quarters. The position peaked at $5.47K in Q4 2022. 127 funds tracked by Wall St. Rank hold KNSA as of Q2 2023.

Ellevest Inc reported no remaining Kiniksa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Ellevest Inc sold 365 Kiniksa Pharmaceuticals shares in Q2 2023, an estimated $3.93K.
Ellevest Inc first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 6 quarters.
Ellevest Inc's Kiniksa Pharmaceuticals position peaked at $5.47K in Q4 2022.
127 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2023.

Based on Ellevest Inc's 13F filing for Q2 2023, filed 9 Aug 2023.